RELX PLC (RELX)
NYSE: RELX · Real-Time Price · USD
49.32
+0.51 (1.04%)
At close: Aug 7, 2025, 4:00 PM
48.44
-0.88 (-1.78%)
Pre-market: Aug 8, 2025, 7:37 AM EDT
Blueprint Medicines Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Blueprint Medicines.
Price Target: $0.00 (0.00%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Blueprint Medicines stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Hold → Buy Upgrades n/a | Hold → Buy | Upgrades | n/a | n/a | Mar 14, 2025 |
| Redburn Atlantic | Redburn Atlantic | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Jan 8, 2025 |
| Goldman Sachs | Goldman Sachs | Hold → Strong Buy Upgrades n/a | Hold → Strong Buy | Upgrades | n/a | n/a | Oct 4, 2023 |
| UBS | UBS | Strong Sell → Hold Upgrades n/a | Strong Sell → Hold | Upgrades | n/a | n/a | Mar 5, 2020 |
| B of A Securities | B of A Securities | Strong Buy Initiates n/a | Strong Buy | Initiates | n/a | n/a | Mar 3, 2020 |
Financial Forecast
Revenue This Year
10.06B
from 9.43B
Increased by 6.66%
Revenue Next Year
10.73B
from 10.06B
Increased by 6.63%
EPS This Year
1.36
from 1.03
Increased by 32.34%
EPS Next Year
1.52
from 1.36
Increased by 11.05%
Financial currency is GBP. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.6B | 11.4B | 12.3B | ||
| Avg | 10.1B | 10.7B | 11.4B | ||
| Low | 9.3B | 9.9B | 10.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.5% | 13.5% | 14.9% | ||
| Avg | 6.7% | 6.6% | 6.6% | ||
| Low | -1.1% | -1.6% | -2.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.45 | 1.61 | 1.74 | ||
| Avg | 1.36 | 1.52 | 1.65 | ||
| Low | 1.26 | 1.41 | 1.51 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 40.2% | 18.2% | 14.8% | ||
| Avg | 32.3% | 11.1% | 9.2% | ||
| Low | 22.3% | 3.2% | -0.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.